MCID: RTC005
MIFTS: 47

Reticulosarcoma

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Reticulosarcoma

MalaCards integrated aliases for Reticulosarcoma:

Name: Reticulosarcoma 12 15 71
Diffuse Large B-Cell Lymphoma 71
Histiocytic Lymphoma 12
Large-Cell Lymphomas 12
Lymphoma, Large-Cell 74
Histiocytic Sarcoma 71
Lymphoma Large Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:8538
ICD9CM 34 200.0
MeSH 43 D008228
NCIt 49 C27824
SNOMED-CT 67 373168002
UMLS 71 C0024302 C0079744 C0334663

Summaries for Reticulosarcoma

MalaCards based summary : Reticulosarcoma, also known as diffuse large b-cell lymphoma, is related to alk-positive anaplastic large cell lymphoma and breast implant-associated anaplastic large cell lymphoma. An important gene associated with Reticulosarcoma is TNFRSF8 (TNF Receptor Superfamily Member 8), and among its related pathways/superpathways are Innate Immune System and nNOS Signaling in Skeletal Muscle. The drugs Vindesine and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Anaplastic large-cell lymphoma (ALCL) is a form of cancer. It is a type of non-Hodgkin lymphoma... more...

Related Diseases for Reticulosarcoma

Diseases related to Reticulosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 641)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 35.1 TNFRSF8 NPM1 ALK
2 breast implant-associated anaplastic large cell lymphoma 34.7 TNFRSF8 TIA1 ALK
3 anaplastic large cell lymphoma 33.8 TNFRSF8 TIA1 PTPRC PAX5 NPM1 MUC1
4 primary cutaneous anaplastic large cell lymphoma 33.8 TIA1 PTPRC NPM1 MUC1 GZMB ALK
5 intravascular large b-cell lymphoma 33.4 BCL6 B2M
6 reticulum cell sarcoma 33.3 TNFRSF8 PTPRC MUC1
7 plasmablastic lymphoma 33.2 PTPRC MUC1 BCL6
8 langerhans cell histiocytosis 32.5 PTPRC FSCN1 CD68
9 peripheral t-cell lymphoma 32.4 TNFRSF8 TIA1 PTPRC PAX5 GZMB BCL6
10 lymphosarcoma 31.9 TNFRSF8 PTPRC BCL6
11 lymphomatoid papulosis 31.4 TNFRSF8 TIA1 NPM1 GZMB ALK
12 hodgkin's lymphoma, lymphocytic-histiocytic predominance 31.2 TNFRSF8 PTPRC BCL6
13 fibrosarcoma of bone 31.1 TNFRSF8 SERPINA3 CD68
14 cutaneous t cell lymphoma 31.0 TRB TNFRSF8 TIA1 GZMB
15 marginal zone b-cell lymphoma 30.9 TNFRSF8 PAX5 BCL6
16 mediastinal malignant lymphoma 30.9 TNFRSF8 PAX5
17 t-cell adult acute lymphocytic leukemia 30.9 TNFRSF8 TIA1 ALK
18 breast lymphoma 30.9 TNFRSF8 PAX5 BCL6 ALK
19 lung lymphoma 30.8 TNFRSF8 PAX5 BCL6
20 mycosis fungoides 30.8 TNFRSF8 TIA1 GZMB ALK
21 spindle cell sarcoma 30.8 SERPINA3 MUC1 CDKN1B
22 panniculitis 30.8 TNFRSF8 TIA1 GZMB CASP3
23 diffuse large b-cell lymphoma 30.8 TNFRSF8 PTPRC PAX5 CCND3 BCL6 B2M
24 mesenchymal cell neoplasm 30.8 SERPINA3 NPM1 CD68 ALK
25 hepatosplenic t-cell lymphoma 30.8 TIA1 GZMB
26 nodular lymphocyte predominant hodgkin lymphoma 30.7 TNFRSF8 PAX5 BCL6
27 lymphoma, hodgkin, classic 30.7 TNFRSF8 TIA1 PTPRC PAX5 GZMB FSCN1
28 angioimmunoblastic t-cell lymphoma 30.7 TNFRSF8 TIA1 GZMB BCL6
29 bone lymphoma 30.6 TNFRSF8 PTPRC PAX5 BCL6 ALK
30 t-cell lymphoma, subcutaneous panniculitis-like 30.6 TRB TNFRSF8 TIA1 GZMB ALK
31 immune deficiency disease 30.5 TNFRSF8 SERPINA3 PTPRC BCL6 B2M
32 histiocytosis 30.5 TNFRSF8 SERPINA3 PTPRC ALK
33 pediatric lymphoma 30.5 TNFRSF8 TIA1 NPM1 BCL6 ALK
34 lymphomatoid granulomatosis 30.5 TIA1 GZMB
35 pleomorphic lipoma 30.4 SERPINA3 CD68
36 sarcoma 30.4 SERPINA3 PTPRC NPM1 MUC1 CASP3 ALK
37 adult lymphoma 30.4 TNFRSF8 BCL6 ALK
38 gastrointestinal lymphoma 30.4 TNFRSF8 SERPINA3 BCL6
39 autoimmune lymphoproliferative syndrome, type v 30.4 TRB TNFRSF8 TIA1 BCL6 ALK
40 aleukemic leukemia cutis 30.4 NPM1 ANPEP
41 t-cell/histiocyte rich large b cell lymphoma 30.4 TNFRSF8 CD68 BCL6
42 tracheal lymphoma 30.4 TNFRSF8 PAX5 BCL6
43 mediastinal cancer 30.4 TNFRSF8 PTPRC PAX5
44 fibrous histiocytoma 30.3 SERPINA3 CD68 ALK
45 central nervous system lymphoma 30.3 PAX5 CD68 BCL6
46 lymphoma, mucosa-associated lymphoid type 30.3 TNFRSF8 PTPRC PAX5 BCL6 B2M
47 mycobacterium tuberculosis 1 30.2 TNFRSF8 SERPINA3 PTPRC GZMB
48 small cell carcinoma 30.1 PTPRC MUC1 ALK
49 t-cell lymphoblastic leukemia/lymphoma 30.0 TNFRSF8 PTPRC CCND3 CASP3
50 plasmacytoma 30.0 PTPRC PAX5 B2M

Graphical network of the top 20 diseases related to Reticulosarcoma:



Diseases related to Reticulosarcoma

Symptoms & Phenotypes for Reticulosarcoma

MGI Mouse Phenotypes related to Reticulosarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 ANPEP B2M BCL6 CASP3 CCND3 CD68
2 immune system MP:0005387 10.2 ANPEP B2M BCL6 CASP3 CCND3 CD68
3 growth/size/body region MP:0005378 10.18 ALK B2M BCL6 CASP3 CCND3 CDKN1B
4 cardiovascular system MP:0005385 10.16 ANPEP B2M BCL6 CASP3 CCND3 CDKN1B
5 endocrine/exocrine gland MP:0005379 10.09 ALK ANPEP B2M BCL6 CASP3 CCND3
6 integument MP:0010771 10 ALK ANPEP B2M BCL6 CASP3 CDKN1B
7 liver/biliary system MP:0005370 9.7 B2M BCL6 CCND3 CDKN1B DCAF8 NPM1
8 neoplasm MP:0002006 9.5 ALK B2M CCND3 CDKN1B NPM1 PAX5
9 respiratory system MP:0005388 9.17 ALK BCL6 CASP3 CCND3 CDKN1B FSCN1

Drugs & Therapeutics for Reticulosarcoma

Drugs for Reticulosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 343)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
2
Epirubicin Approved Phase 4 56420-45-2 41867
3
Pirarubicin Investigational Phase 4 72496-41-4
4 Endothelial Growth Factors Phase 4
5
Apatinib Phase 4 811803-05-1
6
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
7
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
Lenograstim Approved, Investigational Phase 3 135968-09-1
11
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
12
Vinblastine Approved Phase 3 865-21-4 241903 13342
13
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
14
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
15
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
16
Mercaptopurine Approved Phase 3 50-44-2 667490
17
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
18
Lenalidomide Approved Phase 3 191732-72-6 216326
19
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
20
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
21
Venetoclax Approved, Investigational Phase 2, Phase 3 1257044-40-8 49846579
22
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
23
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
24
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
25
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
26
Carmustine Approved, Investigational Phase 3 154-93-8 2578
27
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
28
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
29
Bevacizumab Approved, Investigational Phase 3 216974-75-3
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
31
Phenylalanine Approved, Investigational, Nutraceutical Phase 3 63-91-2 6140
32
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
33
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 5280795 6221
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
35
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
36
protease inhibitors Phase 3
37 HIV Protease Inhibitors Phase 3
38 Hormones Phase 3
39 Antineoplastic Agents, Hormonal Phase 3
40 glucocorticoids Phase 3
41 Hormone Antagonists Phase 3
42 Immunosuppressive Agents Phase 3
43 Anti-Bacterial Agents Phase 3
44 Immunologic Factors Phase 3
45 Tubulin Modulators Phase 3
46 Antibiotics, Antitubercular Phase 3
47 Antirheumatic Agents Phase 3
48 Antimitotic Agents Phase 3
49 Anti-Inflammatory Agents Phase 3
50 Anti-Infective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 992)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
3 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
5 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
6 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
7 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
8 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
9 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
10 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
11 Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma Recruiting NCT04152577 Phase 4 R2-combination chemotherapy;R-combination chemotherapy
12 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
13 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
14 A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B Unknown status NCT01852435 Phase 3 R-CEOP-70;R-CEOP-90;R-CHOP-50
15 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
16 Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study Unknown status NCT02777736 Phase 3 Methotrexate
17 Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03229616 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
18 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
19 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
20 A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients Unknown status NCT02772822 Phase 3 SCT400 plus CHOP;Rituximab plus CHOP
21 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
22 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
23 Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study Unknown status NCT02428751 Phase 3 Pegylated liposomal doxorubicin;Doxorubicin;Rituximab;Cyclophophamide;Vincristine;Prednisone
24 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
25 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
26 International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
27 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
28 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
29 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01014208 Phase 3 OFATUMUMAB + DHAP;RITUXIMAB + DHAP
30 Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab Completed NCT00137995 Phase 3 Rituximab;Etoposide;Carboplatine;Ifosfamide + Mesna;Cisplatine;Cytosine Arabinoside;Dexamethasone;BCNU;Etoposide;Cytarabine;Melphalan
31 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMT CTN #0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
32 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
33 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
34 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Completed NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
35 PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL Completed NCT02951156 Phase 3 Bendamustine;Gemcitabine;Oxaliplatin
36 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
37 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
38 A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Completed NCT00332202 Phase 3 enzastaurin;placebo
39 SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma Completed NCT00491491 Phase 3 ibritumomab tiuxetan
40 Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma. Completed NCT01987505 Phase 3 Rituximab
41 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
42 Intensified CHOP Plus Rituximab (R-CHOP 14) Versus CHOP Plus Rituximab (R-CHOP 21) and Frontline/Prophylactic Darbepoetin Alfa Treatment Versus Usual Symptomatic Treatment of Anemia in Patients Aged 60 to 80 Years With Diffuse Large B-cell Lymphoma. Completed NCT00144755 Phase 3 Darbepoetin alfa
43 A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Completed NCT01197560 Phase 2, Phase 3 Lenalidomide;Gemcitabine;Oxaliplatin;Rituximab;Etoposide
44 Randomized Study of ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients Aged From 18 to 59 Years With Diffuse Large B-cell Lymphoma and a Age-adjusted IPI of 1. Completed NCT00140595 Phase 3 rituximab;doxorubicin;cyclophosphamide
45 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
46 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3
47 An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
48 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
49 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed NCT01855750 Phase 3 Ibrutinib;Placebo;Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone (or equivalent)
50 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab

Search NIH Clinical Center for Reticulosarcoma

Genetic Tests for Reticulosarcoma

Anatomical Context for Reticulosarcoma

MalaCards organs/tissues related to Reticulosarcoma:

40
B Cells, T Cells, Bone, Breast, Liver, Spleen, Thyroid

Publications for Reticulosarcoma

Articles related to Reticulosarcoma:

(show top 50) (show all 1180)
# Title Authors PMID Year
1
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis. 61
31759344 2019
2
Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases. 61
30715765 2019
3
[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma]. 61
29801709 2019
4
Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. 61
29581544 2018
5
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 61
29872609 2018
6
Establishment of a Patient-Derived Xenograft of Canine Enteropathy-Associated T-Cell Lymphoma, Large Cell Type. 61
28011041 2017
7
Comparison of primer sets for T-cell clonality testing in canine intestinal lymphoma. 61
26319600 2015
8
Cytodiagnosis of the primary breast lymphoma in a young woman. 61
24648678 2013
9
Prognostic value of interim (18)F-FDG PET/CT in diffuse large B-cell lymphoma. 61
23372347 2013
10
[Implications of ALK (anaplastic lymphoma kinase) in oncohematology]. 61
20483705 2010
11
Common misdiagnoses in lymphomas and avoidance strategies. 54
20227918 2010
12
Aggressive nasal-type natural killer/T-cell lymphoma associated with Epstein Barr virus presenting as testicular tumor. 54
20415195 2010
13
Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? 61
19526571 2009
14
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. 54
19825801 2009
15
Vitreous metastases of primary cutaneous B-cell lymphoma. 61
19831568 2009
16
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. 54
19275511 2009
17
Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. 54
18670345 2008
18
Domestic and farm-animal exposures and risk of non-Hodgkin's lymphoma in a population-based study in the San Francisco Bay Area. 61
18768507 2008
19
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. 61
18492688 2008
20
[Expression of ALK protein in large cell lymphoma with ALCL chromosome translocation in relation to prognosis]. 54
18549625 2008
21
Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. 54
17694547 2008
22
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. 54
18089725 2007
23
Follicular lymphoma with trisomy 18 exhibiting loss of BCL-2 expression on transformation to a large cell lymphoma. 54
17182663 2007
24
Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma. 54
17464320 2007
25
High prevalence of human polyomavirus JC VP1 gene sequences in pediatric malignancies. 61
17531143 2007
26
Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. 54
17488159 2007
27
Posttransplantation lymphoproliferative disorders in renal transplant recipients: report of over 20 years of experience. 61
17524894 2007
28
CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. 54
17332315 2007
29
Follicular dendritic cell tumor as an unknown primary tumor. 54
17380443 2007
30
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. 54
16825495 2006
31
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. 54
16763206 2006
32
Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. 54
16931956 2006
33
Mortality rates among chemical workers in the Kanawha Valley of West Virginia: 1940-1999. 61
17111678 2006
34
Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. 54
16596703 2006
35
The role of high-dose therapy in peripheral T-cell lymphomas. 54
16640812 2006
36
Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. 54
16451066 2006
37
CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. 54
16412214 2006
38
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. 54
16189272 2006
39
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. 54
16105984 2005
40
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. 54
16151469 2005
41
p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. 54
15990866 2005
42
Activation of alpha-diacylglycerol kinase is critical for the mitogenic properties of anaplastic lymphoma kinase. 54
15928040 2005
43
CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. 54
16061680 2005
44
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. 54
15105810 2004
45
Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. 54
15208656 2004
46
TIA-1 expression in hairy cell leukemia. 54
15073603 2004
47
Risk of sudden death in the Williams-Beuren syndrome. 61
15150772 2004
48
Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. 54
14712286 2004
49
Caspase-3 activation in systemic anaplastic large-cell lymphoma. 54
14657946 2004
50
Mortality among a cohort of uranium mill workers: an update. 61
14691274 2004

Variations for Reticulosarcoma

Expression for Reticulosarcoma

Search GEO for disease gene expression data for Reticulosarcoma.

Pathways for Reticulosarcoma

Pathways related to Reticulosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 TNFRSF8 SERPINA3 PTPRC MUC1 FSCN1 CDKN1B
2
Show member pathways
12.15 PARP1 GZMB CDKN1B CCND3 CASP3
3 11.91 PAX5 GZMB CDKN1B BCL6
4 11.82 TIA1 PARP1 GZMB CASP3
5 11.61 TNFRSF8 PTPRC PAX5 GZMB BCL6 B2M
6 11.44 PAX5 CDKN1B ANPEP
7
Show member pathways
10.86 PARP1 GZMB CASP3

GO Terms for Reticulosarcoma

Biological processes related to Reticulosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.46 MUC1 FSCN1 CASP3 BCL6
2 neutrophil degranulation GO:0043312 9.35 SERPINA3 PTPRC CD68 B2M ANPEP
3 regulation of cell proliferation GO:0042127 8.92 CDKN1B CCND3 BCL6 ALK

Molecular functions related to Reticulosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.02 PTPRC PARP1 NPM1 CDKN1B CCND3
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CDKN1B CASP3

Sources for Reticulosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....